Patents by Inventor Günter HÖGLINGER

Günter HÖGLINGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of synucleinopathies
    Patent number: 10918628
    Abstract: A modulator of PDE1A and/or PDE1C can be used as a medicament, in particular in the prevention or treatment of synucleinopathies, such as multiple system atrophy, dementia with Lewy bodies, Parkinson's disease, pure autonomic failure, rapid eye movement sleep behavior disorder, inherited synucleinopathies caused by mutations or multiplications of the SNCA gene, or synucleinopathies caused by mutations in other genes including, but not limited to, GBA, LRRK2 and PARK2.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: February 16, 2021
    Assignees: DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE), KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN
    Inventors: Günter Höglinger, Matthias Höllerhage, Thomas Werner Rösler
  • Treatment of synucleinopathies
    Publication number: 20190282552
    Abstract: A modulator of PDE1A and/or PDE1C can be used as a medicament, in particular in the prevention or treatment of synucleinopathies, such as multiple system atrophy, dementia with Lewy bodies, Parkinson's disease, pure autonomic failure, rapid eye movement sleep behavior disorder, inherited synucleinopathies caused by mutations or multiplications of the SNCA gene, or synucleinopathies caused by mutations in other genes including, but not limited to, GBA, LRRK2 and PARK2.
    Type: Application
    Filed: October 10, 2017
    Publication date: September 19, 2019
    Applicants: Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Klinikum rechts der lsar der Technischen Universität München
    Inventors: Günter HÖGLINGER, Matthias Höllerhage, Thomas Werner Rösler
  • Perk activator for the treatment of neurodegenerative diseases
    Patent number: 10369123
    Abstract: The present invention relates to a novel method for the treatment and/or prophylaxis of a tau-mediated neurodegenerative disease and/or of a tau-mediated neurodegenerative pathological condition, especially of a neurodegenerative disease and/or of a neurodegenerative pathological condition associated with and/or accompanied by tau aggregation, and in particular for the treatment and/or prophylaxis of a tauopathy; compounds and/or agents and compositions for such treatment and/or prophylaxis, and the manufacture of the compounds and/or agents and compositions suitable for the said treatment and/or prophylaxis. In this regard, the present invention relates especially to the use of compounds acting as PERK activator, a prodrug thereof, a derivative thereof and/or a pharmaceutically acceptable salt of any thereof, as a medicament.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: August 6, 2019
    Assignees: Deutsches Zentrum für Neurodegenerative Erkrankungen E.V. (DZNE), Klinikum Rechts Der Isar Technische Universität München
    Inventors: Günter Höglinger, Julius Bruch, Thomas Rösler
  • PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20170304241
    Abstract: The present invention relates to a novel method for the treatment and/or prophylaxis of a tau-mediated neurodegenerative disease and/or of a tau-mediated neurodegenerative pathological condition, especially of a neurodegenerative disease and/or of a neurodegenerative pathological condition associated with and/or accompanied by tau aggregation, and in particular for the treatment and/or prophylaxis of a tauopathy; compounds and/or agents and compositions for such treatment and/or prophylaxis, and the manufacture of the compounds and/or agents and compositions suitable for the said treatment and/or prophylaxis. In this regard, the present invention relates especially to the use of compounds acting as PERK activator, a prodrug thereof, a derivative thereof and/or a pharmaceutically acceptable salt of any thereof, as a medicament.
    Type: Application
    Filed: August 14, 2015
    Publication date: October 26, 2017
    Inventors: Günter HÖGLINGER, Julius BRUCH, Thomas RÖSLER